OXB acquires commercial-scale viral vector facility in North Carolina for $4.5M

Core Insights - OXB has acquired a custom-built cell and gene therapy viral vector manufacturing facility in North Carolina, enhancing its US manufacturing capabilities and GMP capacity [1] - The FDA-approved facility will support late-stage programs and commercial launches, particularly in the adeno-associated virus sector [1] - The acquisition aligns with OXB's strategic initiatives to expand its US commercial capabilities and is expected to generate a single-digit gain in 2025 [1] Acquisition Details - The facility was purchased for $4.5 million, funded by existing cash, and integration planning has already begun [1] - The site includes two operational GMP drug substance suites, a dedicated fill-finish suite, and additional expansion-ready GMP suites [1] - OXB's Bedford, MA site will continue to focus on early-stage development, while the new North Carolina site will serve as a hub for clinical and commercial activities [1] Strategic Implications - The acquisition is part of OXB's broader strategy to strengthen its CDMO network and increase US commercial-scale GMP capacity [1] - The company plans to invest in the new facility, including hiring additional operational staff to enhance fill-finish capacity and client onboarding [1] - Investment plans remain consistent with those announced in August 2025, focusing on meeting growing client demand [1]